The Chinese government's 14th Five-Year Plan for healthcare specifically identifies diabetes management as a chronic disease prevention priority, with investment in guideline-based pharmacotherapy programs that are driving adoption of evidence-based GLP-1 therapy in public healthcare settings Middle East & Africa and Latin America GLP-1 Receptor Agonist Market Insights The Middle East represents a commercially interesting GLP-1 market because the Gulf states combine high rates of type 2 diabetes and obesity the UAE's adult obesity rate exceeds 37%, among the world's highest with high-income consumer populations and expanding private health insurance coverage
Dermal toxicity studies of technical polychlorinated biphenyls and fractions thereof in rabbits
mild hepatic impairment, n = 7
When BxPC-3 cells were treated with the drug formulations, an increase in scratch area was noted in the ORI@Lipo (ORI 5 g/mL), ORI@CPD-Lipo (ORI 5 g/mL), and ORI@CPD-Lipo plus CKAAKN (ORI 5 g/mL) groups compared to the control, indicating that the drug-loaded liposomes suppressed BxPC-3 cell migration
Similar immune defects are observed in alcohol-related cirrhosis, including depletion and functional impairment of MAIT (mucosal-associated invariant T) cells and elevated soluble immune checkpoint molecules, such as sTIM-3 (62)
This article is exclusive to STAT+ subscribers Unlock this article plus daily intelligence on Capitol Hill and the life sciences industry by subscribing to STAT+
